• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Nichol Geoffrey

    6/14/24 6:05:09 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPST alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    NICHOL GEOFFREY

    (Last) (First) (Middle)
    C/O TEMPEST THERAPEUTICS, INC.
    2000 SIERRA POINT PARKWAY, SUITE 400

    (Street)
    BRISBANE CA 94005

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tempest Therapeutics, Inc. [ TPST ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $3.03 06/13/2024 A 16,000 (1) 06/12/2034 Common Stock 16,000 $0 16,000 D
    Explanation of Responses:
    1. The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
    /s/ Nicholas Maestas, Attorney-in-Fact for Geoffrey Nichol 06/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TPST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TPST

    DatePrice TargetRatingAnalyst
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    4/10/2025Buy → Neutral
    H.C. Wainwright
    3/14/2024$13.00Sector Outperform
    Scotiabank
    2/8/2024$15.00Buy
    Jefferies
    10/21/2021Outperform
    William Blair
    7/13/2021$51.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TPST
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Tempest Therapeutics Inc.

      10-K/A - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/30/25 4:05:19 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tempest Therapeutics Inc.

      8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/28/25 9:49:42 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tempest Therapeutics Inc.

      8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/18/25 4:16:40 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Brady Stephen R

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:25 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Maestas Nicholas

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:20 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Corporate Controller Trojanowski Justin

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:22 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/8/24 4:15:11 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/3/24 7:35:42 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/2/24 4:15:14 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

      BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation of new data supporting the immune component of amezalpat's purported dual mechanism of action that reinforces its potential as a novel cancer treatment at the 2025 American Association for Cancer Research (AACR) Annual Meeting. "The data presented at the AACR Annual Meeting show that amezalpat reduced tumor promoting immunosuppression by M2 macrophages and T regulatory cells resulting in immune activation. These data support the immune

      4/28/25 4:05:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

      BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TPST-1495, the company's novel dual receptor inhibitor of prostaglandin (PGE2) signaling, for the treatment of patients with Familial Adenomatous Polyposis (FAP). "Receiving orphan drug designation for TPST-1495, our second clinical program, is a significant milestone in our mission to bring innovative therapies to patients with unmet medical need," said Stephen Br

      4/21/25 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

      Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC Received FDA "Study May Proceed" letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis (FAP); data expected 2026 BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the c

      4/9/25 4:30:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

      SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      8/12/24 8:59:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

      SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      5/13/24 4:54:01 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tempest Therapeutics Inc. (Amendment)

      SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      2/14/24 6:49:42 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Leadership Updates

    Live Leadership Updates

    See more
    • Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

      BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John

      9/18/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

      BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. "Troy brings a wealth of experience in late-stage product development, including managing quality systems across a range of global clinical studies and assisting with global regulatory filings. We look forward to her contributions as we move towards Phase 3 development of amezalpat to treat hepatocellular carcinoma and are thrilled to have her join the Tempest leadership team,"

      8/21/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

      BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors.   Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer

      11/11/21 9:00:00 AM ET
      $QGEN
      $TPST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tempest Therapeutics downgraded by Scotiabank

      Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

      4/10/25 8:50:49 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

      4/10/25 8:03:29 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Tempest Therapeutics with a new price target

      Scotiabank initiated coverage of Tempest Therapeutics with a rating of Sector Outperform and set a new price target of $13.00

      3/14/24 8:21:09 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPST
    Financials

    Live finance-specific insights

    See more
    • Tempest Extends Limited Duration Stockholder Rights Plan

      BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or the "Company"), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the "Board") has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan until the Annual Meeting of Stockholders. "Given the significant milestones reached this year in the amezalpat program – the positive survival data compared to standard of care and broad agreement with FDA on the Phase 3 path – coupled

      10/10/24 7:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

      21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves OS is the primary regulatory endpoint for first-line HCCCompany to host webcast conference call today at 8:30am ET BRISBANE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new positive data from the ongoing global randomized Phase 1b/2 clinica

      6/20/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

      BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register onlin

      6/18/24 6:22:51 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care